长期的实践经验表明,在患有巨症的患者中减少了巨的剂量
Nelma Verônica Marques1, Luiz Eduardo Armondi Wildemberg2, Monica R Gadelha3
1N Marques, Centro de Pesquisa em Neuroendocrinologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Endocrine connections
|August 2, 2023
概括
帕西雷奥提德有效控制了壮症. 一些患者的剂量减少维持了正常的胰岛素样生长因子I (IGF-I) 水平和改善的葡萄糖控制,这表明对管理高血糖的潜在益处.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 巨症是一种由生长激素过量引起的慢性疾病.
- 长效释放的帕西里欧提德是一种治疗选择,用于控制不充分的壮症.
- 第一线疗法可能无法在所有患者中实现生化控制.
研究的目的:
- 为了评估长期的,现实世界的有效性,在壮病的 pasireotide.
- 评估降低沙雷胺剂量对生化控制和血糖参数的影响.
- 为了确定剂量降低在管理化相关高血糖的潜在好处.
主要方法:
- 一项长期的现实研究,涉及50名患有壮病的患者.
- 监测胰岛素样生长因子I (IGF-I),葡萄糖和糖化血红蛋白水平.
- 在一小部分患者 (20/50) 中对发胺剂量降低的分析.
主要成果:
- 帕西雷奥提德在患者中实现了生化控制和减少瘤体积.
- 减少剂量对50名患者中的20名患者有益,维持正常的IGF-I水平.
- 早期响应者 (1-3个月) 和后期响应者 (≥4个月) 显示持续的IGF-I控制后剂量减少.
- 经过减小发胺剂量后,葡萄糖和糖化血红蛋白水平下降.
结论:
- 帕西雷奥提德对壮症的治疗有效,包括减少瘤体积.
- 降低帕西里奥提德剂量可以保持生化控制并改善血糖参数.
- 需要进一步的研究来确定可能从降低剂量来管理高血糖症中受益的患者.
相关概念视频
01:16Insulin: Dosing Regimen and Adverse Effects
209
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
209
01:20Desensitization and Tachyphylaxis
1.8K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.8K
01:01Dosage Regimen: Fixed Dose
1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215
01:24Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
01:11Renal Failure: Dose Adjustments
122
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
122